Zai Lab Revenue Triples, as It Struggles to Break Cycle of Mounting Losses
The biotech company is bringing in bigger sums from its growing stable of drugs approved for sale in China, but is also accelerating its R&D spending Key takeaways: Zai Lab…
RELATED ARTICLES
-
FAST NEWS: Zai Lab’s loss narrows on growing revenue
ZLAB.US 9688.HK
-
FAST NEWS: Zai Lab’s loss narrows on strengthening sales
9688.HK ZLAB.US
-
Everest reaches new heights on growing drug sales
1952.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
HBM gets health boost from drug licensing deals
2142.HK
Discover hidden China stock gems in our weekly newsletter